Edwards Lifesciences Corp's market capitalization of $54,365,946,854 is ahead of 95.63% of US-listed equities.
EW's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,190.3 -- higher than 98.02% of US-listed equities with positive expected earnings growth.
In terms of volatility of its share price, EW is more volatile than 93.42% of stocks we're observing.
Stocks that are quantitatively similar to EW, based on their financial statements, market capitalization, and price volatility, are BSX, PHG, ILMN, KLAC, and ADI.
EW's SEC filings can be seen here. And to visit Edwards Lifesciences Corp's official web site, go to www.edwards.com.
Edwards Lifesciences provides products and technologies to treat structural heart disease and critically ill patients worldwide. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company was founded in 1999 and is based in Irvine, California.
EW Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for EW, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Edwards Lifesciences Corp ranked in the 10th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for EW, they are:
The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.04%; that's greater than only 19.35% of US stocks we're applying DCF forecasting to.
The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 7.13% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than just 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as EW, try BHC, SRDX, COO, SIGA, and OSMT.
Shares of E.W. Scripps spiked 13% in Friday’s extended market trading after the TV station owner disclosed that Warren Buffett’s Berkshire Hathaway has a 24.9% passive stake in the company. According to an SEC filing, billionaire investor Buffett owns 23.1 million shares of E.W. Scripps (SSP), which are held in the form of a warrant exercisable within 60 days. Back in September, Buffett agreed to make a $600 million equity investment in E.W. Scripps to help the company buy broadcast network ION Media for $2.65 billion. In exchange, Berkshire received a warrant to purchase 23.1 million in Class A E.W. Scripps shares at $13 a piece. E.W.
The Prosthetic Heart Valves market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. Coherent Market Inisghts Research’s latest publication, titled Prosthetic
IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesday, January 27, 2021, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877)… Read More »Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021
Investment Thesis We are bullish Edwards Lifesciences (NYSE:EW) shares and believe the name is worth visiting for those seeking exposure to valve therapies and cardiovascular interventions. EW hosts a robust portfolio that is well insulated, via diversified offerings within the valve surgery space, and this widens the company's economic bastion...